AKAM vs TCRX · P/E 27, rev $2.17B vs rev $2.0M
Akamai Technologies Inc (AKAM) versus Tscan Therapeutics Inc (TCRX) — a side-by-side from cached financials, not a winner call.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Latest reported TCRX revenue for 2026-06-30 was $2.0M. Net income was -$59.0M. TCRX currently screens at market cap $62.1M.
AKAM currently screens at market cap $11.31B and trailing P/E 26.7. TCRX currently screens at market cap $62.1M.
Not investment advice. Open the AKAM and TCRX stock pages for the full models.
Not investment advice.